相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PCSK9Qβ-003 Vaccine Attenuates Atherosclerosis in Apolipoprotein E-Deficient Mice
Danyu Wu et al.
CARDIOVASCULAR DRUGS AND THERAPY (2021)
PCSK9 and LRP5 in macrophage lipid internalization and inflammation
Lina Badimon et al.
CARDIOVASCULAR RESEARCH (2021)
PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36
Zhiyong Qi et al.
CIRCULATION (2021)
PCSK9 genetic variants and cognitive abilities: a large-scale Mendelian randomization study
Donald M. Lyall et al.
ARCHIVES OF MEDICAL SCIENCE (2021)
PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Goes DAMP
Roy L. Silverstein
CIRCULATION (2021)
PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database
Gabriella di Mauro et al.
DRUG SAFETY (2021)
New Insight Into Metformin-Induced Cholesterol-Lowering Effect Crosstalk Between Glucose and Cholesterol Homeostasis via ChREBP (Carbohydrate-Responsive Element-Binding Protein)-Mediated PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Regulation
Die Hu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2021)
Dynamin-related protein 1 inhibition reduces hepatic PCSK9 secretion
Maximillian A. Rogers et al.
CARDIOVASCULAR RESEARCH (2021)
Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function
Stephane Ramin-Mangata et al.
ATHEROSCLEROSIS (2021)
Substantial PCSK9 inactivation in β-cells does not modify glucose homeostasis or insulin secretion in mice
Marie-Line Peyot et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2021)
Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9
Carlota Oleaga et al.
JOURNAL OF LIPID RESEARCH (2021)
Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface-expression of LDLR and CD36 and NLRP3 inflammasome
Yannick Cyr et al.
PHYSIOLOGICAL REPORTS (2021)
Blood flow patterns regulate PCSK9 secretion viaMyD88-mediated pro-inflammatory cytokines
Shijie Liu et al.
CARDIOVASCULAR RESEARCH (2020)
Lipid Lowering and Alzheimer Disease Risk: A Mendelian Randomization Study
Dylan M. Williams et al.
ANNALS OF NEUROLOGY (2020)
Surf4 regulates expression of proprotein convertase subtilisin/kexin type 9 (PCSK9) but is not required for PCSK9 secretion in cultured human hepatocytes
Yishi Shen et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2020)
Advances in the molecular mechanisms of NLRP3 inflammasome activators and inactivators
Dongling Liu et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Accumulation of Pericardial Fat Is Associated With Alterations in Heart Rate Variability Patterns in Hypercholesterolemic Pigs
Domingo E. Uceda et al.
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY (2020)
Cognition After Lowering LDL-Cholesterol With Evolocumab
Baris Gencer et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9 The Role of STAT3
Chiara Macchi et al.
AMERICAN JOURNAL OF PATHOLOGY (2020)
Circulating Rather Than Intestinal PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Regulates Postprandial Lipemia in Mice
Damien Garcon et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2020)
The role of the C-terminal domain of PCSK9 and SEC24 isoforms in PCSK9 secretion
Shi-jun Deng et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2020)
Evolocumab, a PCSK9-Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia
Thorsten M. Leucker et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders
Emma M. O'Connell et al.
FRONTIERS IN NEUROSCIENCE (2020)
Hydrogen sulfide accumulates LDL receptor precursor via downregulating PCSK9 in HepG2 cells
Yong Huang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2020)
PCSK9 Expression in Epicardial Adipose Tissue: Molecular Association with Local Tissue Inflammation
Elena Dozio et al.
MEDIATORS OF INFLAMMATION (2020)
Unlike estrogens that increase PCSK9 levels post-menopause HSP27 vaccination lowers cholesterol levels and atherogenesis due to divergent effects on PCSK9 and LDLR
Nadia Maarouf et al.
PHARMACOLOGICAL RESEARCH (2020)
Depression and cardiovascular risk-association among Beck Depression Inventory, PCSK9 levels and insulin resistance
C. Macchi et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer
Xinjian Liu et al.
NATURE (2020)
Genetic and In Vitro Inhibition of PCSK9 and Calcific Aortic Valve Stenosis
Nicolas Perrot et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2020)
Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin tyoe-9 and is required for the degration of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9
Hyun-Duk Jang et al.
EUROPEAN HEART JOURNAL (2020)
NLRP3 inflammasome via IL-1 13 regulates PCSK9 secretion
Zufeng Ding et al.
THERANOSTICS (2020)
Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities
Binlu Huang et al.
NATURE METABOLISM (2020)
PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor
Lorenzo Da Dalt et al.
EUROPEAN HEART JOURNAL (2019)
Apolipoprotein E/Amyloid-β Complex Accumulates in Alzheimer Disease Cortical Synapses via Apolipoprotein E Receptors and Is Enhanced by AP0E4
Tina Bilousova et al.
AMERICAN JOURNAL OF PATHOLOGY (2019)
Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia
Wieneke Dijk et al.
DIABETES OBESITY & METABOLISM (2019)
Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer's Disease
Maria Pia Adorni et al.
FRONTIERS IN AGING NEUROSCIENCE (2019)
PCSK9 inhibition and inflammation: A narrative review
Massimiliano Ruscica et al.
ATHEROSCLEROSIS (2019)
PCSK9 is Expressed in Human Visceral Adipose Tissue and Regulated by Insulin and Cardiac Natriuretic Peptides
Marica Bordicchia et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals
Chiara Macchi et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2019)
Potential anti-tumor effect of a nanoliposomal antiPCSK9 vaccine in mice bearing colorectal cancer
Amir Abbas Momtazi-Borojeni et al.
ARCHIVES OF MEDICAL SCIENCE (2019)
Effects of immunization against PCSK9 in an experimental model of breast cancer
Amir Abbas Momtazi-Borojeni et al.
ARCHIVES OF MEDICAL SCIENCE (2019)
Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors
Christopher P. Nelson et al.
CIRCULATION-GENOMIC AND PRECISION MEDICINE (2019)
PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction
Hua Sun et al.
JOURNAL OF LIPID RESEARCH (2018)
PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages
Zufeng Ding et al.
CARDIOVASCULAR RESEARCH (2018)
PCSK9 as a Positive Modulator of Platelet Activation
Marina Camera et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?
Wieneke Dijk et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2018)
PCSK9 induces a pro-inflammatory response in macrophages
Chiara Ricci et al.
SCIENTIFIC REPORTS (2018)
A Mendelian randomization study of the effects of blood lipids on breast cancer risk
Christoph Nowake et al.
NATURE COMMUNICATIONS (2018)
The cargo receptor SURF4 promotes the efficient cellular secretion of PCSK9
Brian T. Emmer et al.
ELIFE (2018)
Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease
Francesca Zimetti et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
Christine Landlinger et al.
EUROPEAN HEART JOURNAL (2017)
Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study
Eliano P. Nayarese et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response
Teik Chye Ooi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Translating the biology of adipokines in atherosclerosis and cardiovascular diseases: Gaps and open questions
M. Ruscica et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2017)
PCSK9 regulates apoptosis in human lung adenocarcinoma A549 cells via endoplasmic reticulum stress and mitochondrial signaling pathways
Xiaohui Xu et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2017)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) Deficiency is Protective Against Venous Thrombosis in Mice
Hui Wang et al.
SCIENTIFIC REPORTS (2017)
PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans
Andrea Baragetti et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2017)
Circulating PCSK9 levels in acute coronary syndrome: Results from the PC-SCA-9 prospective study
B. Cariou et al.
DIABETES & METABOLISM (2017)
New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway
Zhi-Han Tang et al.
ATHEROSCLEROSIS (2017)
Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice
Lei Sun et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2017)
Local effects of human PCSK9 on the atherosclerotic lesion
Ilaria Giunzioni et al.
JOURNAL OF PATHOLOGY (2016)
Evaluation of plasma PCSK9 concentrations, transcript of LDL receptor, as well as the total number of monocyte LDL receptors in acute coronary syndrome patients
Pawel Burchardt et al.
CARDIOLOGY JOURNAL (2016)
Effect of Leptin Replacement on PCSK9 in ob/ob Mice and Female Lipodystrophic Patients
Amy E. Levenson et al.
ENDOCRINOLOGY (2016)
Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence
Nicola Ferri et al.
TRANSLATIONAL RESEARCH (2016)
Hemodynamic Shear Stress via ROS Modulates PCSK9 Expression in Human Vascular Endothelial and Smooth Muscle Cells and Along the Mouse Aorta
Zufeng Ding et al.
ANTIOXIDANTS & REDOX SIGNALING (2015)
PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver
Annie Demers et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Cross-talk between LOX-1 and PCSK9 in vascular tissues
Zufeng Ding et al.
CARDIOVASCULAR RESEARCH (2015)
Role of PCSK9 beyond liver involvement
Bertrand Cariou et al.
CURRENT OPINION IN LIPIDOLOGY (2015)
Variable effects of gender and Western diet on lipid and glucose homeostasis in aged PCSK9-deficient C57BL/6 mice
Majambu Mbikay et al.
JOURNAL OF DIABETES (2015)
The Hypercholesterolemia-Risk Gene SORT1 Facilitates PCSK9 Secretion
Camilla Gustafsen et al.
CELL METABOLISM (2014)
Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor-Dependent and -Independent Mechanisms
Shirya Rashid et al.
CIRCULATION (2014)
Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin
Susan Kuhnast et al.
JOURNAL OF LIPID RESEARCH (2014)
Transintestinal Cholesterol Excretion Is an Active Metabolic Process Modulated by PCSK9 and Statin Involving ABCB1
Cedric Le May et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2013)
PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells
Emile Levy et al.
ATHEROSCLEROSIS (2013)
SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion
Xiao-Wei Chen et al.
ELIFE (2013)
Proprotein Convertase Subtilisin/Kexin Type 9 Interacts With Apolipoprotein B and Prevents Its Intracellular Degradation, Irrespective of the Low-Density Lipoprotein Receptor
Hua Sun et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
The M2 Module of the Cys-His-rich Domain (CHRD) of PCSK9 Protein Is Needed for the Extracellular Low-density Lipoprotein Receptor (LDLR) Degradation Pathway
Yascara Grisel Luna Saavedra et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice
Ding Ai et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Discovery of a New Role of Human Resistin in Hepatocyte Low-Density Lipoprotein Receptor Suppression Mediated in Part by Proprotein Convertase Subtilisin/Kexin Type 9
Michelle Melone et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue
Anna Roubtsova et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors
Oystein L. Holla et al.
JOURNAL OF LIPID RESEARCH (2011)
PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke
Estelle Rousselet et al.
JOURNAL OF LIPID RESEARCH (2011)
Increased Secretion of Lipoproteins in Transgenic Mice Expressing Human D374Y PCSK9 Under Physiological Genetic Control
Bronwen Herbert et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities
Majambu Mbikay et al.
FEBS LETTERS (2010)
PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain
Mali Liu et al.
JOURNAL OF LIPID RESEARCH (2010)
Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters
Bin Dong et al.
JOURNAL OF LIPID RESEARCH (2010)
Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial Triglyceridemia
Cedric Le May et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
PCSK9 is expressed in pancreatic δ-cells and does not alter insulin secretion
Cedric Langhi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Central nervous system: cholesterol turnover, brain development and neurodegeneration
John M. Dietschy
BIOLOGICAL CHEMISTRY (2009)
Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation EVIDENCE FOR AN INTRACELLULAR ROUTE
Steve Poirier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance
Jungsu Kim et al.
NEURON (2009)
PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1
Mary Cabell Jonas et al.
EMBO REPORTS (2008)
Proprotein convertase Subtilisin/Kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
Ahmed Zaid et al.
HEPATOLOGY (2008)
Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2
Hyun Jeong Jeong et al.
JOURNAL OF LIPID RESEARCH (2008)
LDL receptor deficiency results in decreased cell proliferation and presynaptic bouton density in the murine hippocampus
Monique Mulder et al.
NEUROSCIENCE RESEARCH (2007)
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation
Da-Wei Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia
David Cunningham et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2007)
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice
Thomas A. Lagace et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system
Steve Poirier et al.
JOURNAL OF NEUROCHEMISTRY (2006)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment
KN Maxwell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Macropinocytosis is the endocytic pathway that mediates macrophage foam cell formation with native low density lipoprotein
HS Kruth et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Proprotein convertase models based on the crystal structures of furin and kexin: Explanation of their specificity
S Henrich et al.
JOURNAL OF MOLECULAR BIOLOGY (2005)
Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9
K Ouguerram et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes
JD Horton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):: Liver regeneration and neuronal differentiation
NG Seidah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Functional characterization of Narc 1, a novel proteinase related to proteinase K
S Naureckiene et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2003)
分享论文
